MedTrace Logo

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

NCT05900895 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-11-20

No results posted yet for this study

Summary

Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

Conditions

Interventions

DRUG

Olaparib

Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.

DRUG

17b-estradiol

17b-estradiol will be taken orally three times per day.

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • Mary D Chamberlin

    lead OTHER

Principal Investigators

  • Mary Chamberlin, MD · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900895 on ClinicalTrials.gov